Cover Image
市場調查報告書

癌症標記市場

Cancer Markers

出版商 Kalorama Information 商品編碼 355640
出版日期 內容資訊 英文 155 Pages
訂單完成後即時交付
價格
Back to Top
癌症標記市場 Cancer Markers
出版日期: 2016年03月24日 內容資訊: 英文 155 Pages
簡介

癌症是次於心臟病的死因第二名,2012年的全球癌症發病數量是1,406萬8,000件。最常見的是乳癌和大腸癌、肺癌、前列腺癌,以歐美為中心擴展著。還有其他的關於癌症,新的生物標記和治療方法,診斷檢驗也被開發。

本報告提供過去10∼15年的癌症診斷技術的歷史相關驗證,今後至2020年的市場預測,各市場區隔趨勢,以及參與企業簡介彙整。

第1章 摘要整理

第2章 簡介

  • 癌症風險評估
  • 癌症篩檢
  • 癌症監測
  • 癌症預後評估
  • 個人化醫療/精密檢驗
  • 癌症生物標記的競爭
  • 分子標記
  • 精密醫療

第3章 癌症標記市場分析

第4章 企業簡介

  • 20/20 GeneSystems, Inc
  • Abbott Laboratories
  • Abcodia Ltd.
  • Alere Inc.
  • Ambry Genetics Corp.
  • Asuragen, Inc.
  • Athena Diagnostics, Inc.
  • bioMerieux SA
  • Immunodiagnostics for Lab Professionals
  • bioTheranostics, Inc.
  • Cancer Genetics, Inc.
  • Genomic Health, Inc.
  • Genoptix
  • Hologic, Inc
  • Illumina, Inc.
  • Myriad Genetics, Inc.
  • QIAGEN N.V.
  • Roche
  • Roche Professional Diagnostics
  • Thermo Fisher Scientific, Inc.
  • Wako Pure Chemical Industries, Ltd.,

圖表

目錄
Product Code: KLI5948135

Cancer Markers provides market assessment, estimate and competitive analysis for tests for oncology that use biomarkers. This includes a range of technologies made by scores of companies. These type of tests have demonstrated faster revenue growth than IVD broadly, and drawn considerable interest from competitors. The report contains products designed to determine risk for cancer, screen for cancer, test for cancer, aid in prognosis and personalize therapy. Among the technologies are the following:

  • Histology/Cytology:
  • Immunohistochemistry
  • In situ hybridization
  • Immunoassays - Tumor Markers:
  • Flow Cytometry
  • Rapid Tests:
  • Molecular Marker-Based

Estimates for these segments are provided for 2015 and 2020. In addition, some specific marker breakouts are provided along with significant detail of products on the market.

This report reviews the progression of cancer diagnostic technologies over the past 10-15 years and notes some trends in test strategies as well, including:

  • Cancer Risk Assessment
  • Cancer Screening
  • Cancer Monitoring
  • Cancer Prognosis Assessment
  • Personalized Medicine/Precision Testing
  • Competition in Cancer Biomarkers
  • Molecular Markers
  • Precision Medicine

Cancer Markers provides the following data:

  • Worldwide Cancer Biomarkers Diagnostic Market - 2015 and 2020 (IHC, ISH, Immunoassays, Flow, Rapid, Molecular)
  • Selected International Agreements
  • Worldwide Cancer Biomarkers Diagnostic Market Percentage (IHC, ISH, Flow Cytometry, Molecular-Based Assays, NMP22, FOB, PSA, CEA, CA125, AFP, Other Tumor Markers)
  • Estimated Global Incidence and Mortality due to Cancer, 2012 - By Regions of the World
  • Selected Widely Used Tumor Markers
  • Selected Biomarkers and Biomarker Panels to Assess Risk of Cancer, and Companies Developing/Marketing These Biomarkers
  • Selected Biomarkers and Biomarker Panels for Cancer Screening, and Companies Developing/Marketing These Biomarkers
  • Selected Biomarkers and Biomarker Panels for Diagnosis and/or Monitoring of Cancer, and Companies Developing/Marketing These Biomarkers
  • Selected Biomarkers and Biomarker Panels to Predict Prognosis of Cancer, and Companies Developing/Marketing These Biomarkers
  • Selected Biomarkers and Biomarker Panels to Predict Response to Therapy, and Companies Developing/Marketing These Biomarkers
  • Selected FDA Cleared/Approved Companion Diagnostic Tests, and Companies Developing/Marketing These Biomarkers
  • Selected Companies Developing/Marketing Cancer Tests
  • Common Next Generation Molecular Test Traits
  • Selected Sample Preparation Reagents
  • Selected Cancer Test Innovations, 2015

Cancer is the number two cause of death, behind only cardiovascular disease. Cancer affects people worldwide. Every region of the world, and every country, is affected. The International Agency for Cancer, World Health Organization, reports that the estimated incidence of cancer worldwide in 2012 was 14,068,000. The most common types of cancer worldwide include breast cancer, colorectal cancer, lung cancer, and prostate cancer. These are common cancers in the United States and Europe, and are the focus of much therapeutic and diagnostic activities, and thus also the target of much of the cancer biomarker activity. It is important to remember, though, that novel biomarkers, therapies, and diagnostic tests are also being developed for other types of cancers.

This report contains company profiles, including coverage of the following:

  • 20/20 GeneSystems, Inc.
  • Abbott Laboratories
  • Abcodia Ltd.
  • Alere Inc. (Abbott)
  • Ambry Genetics Corp.
  • Asuragen, Inc.
  • Athena Diagnostics, Inc.
  • bioMérieux SA
  • bioTheranostics, Inc.
  • Cancer Genetics, Inc.
  • Genomic Health, Inc.
  • Genoptix (A Novartis Company)
  • Hologic, Inc.
  • Illumina, Inc.
  • Myriad Genetics, Inc.
  • QIAGEN N.V.
  • Roche
  • Thermo Fisher Scientific, Inc.
  • Wako Pure Chemical Industries, Ltd.

The various clinical techniques and trends are discussed from the point of view of their present and potential market impact. Therefore, the report does not provide an in depth discussion of the etiology, physiology and clinical manifestations of diseases except where an understanding of these areas is required to understand the impact that new and early diagnostics exert on patient care. Similarly, the report does not describe the technical aspects of the test modalities used in PMx tests.

The information presented in this report is derived on publicly available information sources such as company, government, and medical organization reports. The analysis is based on the author's industry knowledge combined with literature searches and interviews with industry professionals and experts in the areas of in vitro diagnostics and personalized medicine.

Table of Contents

ONE: EXECUTIVE SUMMARY

  • Market
  • Scope and Methodology

TWO: INTRODUCTION

  • Cancer Risk Assessment
  • Cancer Screening
  • Cancer Monitoring
  • Cancer Prognosis Assessment
  • Personalized Medicine/Precision Testing
  • Competition in Cancer Biomarkers
  • Molecular Markers
  • Precision Medicine

THREE: CANCER MARKERS MARKET ANALYSIS

FOUR: COMPANY PROFILES

  • 20/20 GeneSystems, Inc
  • Abbott Laboratories
    • Recent Revenue History
    • Agreements
  • Abcodia Ltd.
    • Financings
  • Alere Inc. (Abbott)
  • Ambry Genetics Corp.
  • Asuragen, Inc.
    • Diagnostic Products
    • Translational/Companion Diagnostics
    • Agreements
  • Athena Diagnostics, Inc. (A Quest Diagnostics Business)
  • bioMérieux SA
    • Recent Revenue History
    • Company Overview
    • Immunodiagnostics for Lab Professionals (Clinical Laboratories)
    • Molecular Diagnostics
  • bioTheranostics, Inc. (A bioMérieux Company)
  • Cancer Genetics, Inc.
    • Recent Revenue History
    • Company Overview
    • Agreements
  • Genomic Health, Inc.
    • Recent Revenue History
  • Genoptix (A Novartis Company)
  • Hologic, Inc.
    • Recent Revenue History
    • Company Overview
  • Illumina, Inc.
    • Recent Revenue History
    • Company Overview
  • Myriad Genetics, Inc.
    • Recent Revenue History
    • Company Overview
  • QIAGEN N.V.
    • Recent Revenue History
  • Roche
    • Recent Revenue History
    • Company Overview
    • Roche Professional Diagnostics
    • Molecular Diagnostics
    • Tissue Diagnostics
  • Thermo Fisher Scientific, Inc.
    • Recent Revenue History
    • Company Overview
  • Wako Pure Chemical Industries, Ltd.,

LIST OF EXHIBITS

ONE: EXECUTIVE SUMMARY

  • Figure 1-1: Cases of Cancer by Type
  • Figure 1-2: Cancer Marker-Based Test Market, 2015 and 2020

TWO: INTRODUCTION

  • Table 2-1: Estimated Global Incidence and Mortality due to Cancer, 2012 - By Regionsnof the World
  • Table 2-2: Selected Widely Used Tumor Markers
  • Table 2-3: Selected Biomarkers and Biomarker Panels to Assess Risk of Cancer, and Companies Developing/Marketing These Biomarkers
  • Table 2-4: Selected Biomarkers and Biomarker Panels for Cancer Screening, and Companies Developing/Marketing These Biomarkers
  • Table 2-5: Selected Biomarkers and Biomarker Panels for Diagnosis and/or Monitoring of Cancer, and Companies Developing/Marketing These Biomarkers
  • Table 2-6: Selected Biomarkers and Biomarker Panels to Predict Prognosis of Cancer,and Companies Developing/Marketing These Biomarkers
  • Table 2-7: Selected Biomarkers and Biomarker Panels to Predict Response to Therapy,and Companies Developing/Marketing These Biomarkers
  • Table 2-8: Selected FDA Cleared/Approved Companion Diagnostic Tests, and Companies Developing/Marketing These Biomarkers
  • Table 2-9: Selected Companies Developing/Marketing Cancer Tests
  • Table 2-10: Common Next Generation Molecular Test Traits
  • Table 2-11: Selected Sample Preparation Reagents
  • Table 2-12: Selected Cancer Test Innovations, 2015

THREE: CANCER MARKERS MARKET ANALYSIS

  • Table 3-1: Worldwide Cancer Biomarkers Diagnostic Market - 2015 and 2020 (IHC,ISH, Immunoassays, Flow, Rapid, Molecular)
  • Table 3-2: Selected International Agreements
  • Figure 3-1: Worldwide Cancer Biomarkers Diagnostic Market Percentage (IHC, ISH,Flow Cytometry, Molecular-Based Assays, NMP22, FOB, PSA, CEA, CA125, AFP,Other Tumor Markers)
Back to Top